Pelosi Slams This 78% Healthcare Portfolio for Missing the CHIPS Act

Welcome. I have thoroughly reviewed the disclosures you've provided regarding your financial holdings. It reads less like an investment portfolio and more like the witness list for a House Energy and Commerce subcommittee hearing on pharmaceuticals. I have always maintained that we must invest in the health and well-being of the American people, but my goodness, you took that directive quite literally, didn't you?

I have built a rather successful track record by simply paying very, very close attention to the fundamentals of American innovation and the undeniable tailwinds of public policy. What we have here is a collection of undeniably robust institutions, yet the assembly of this legislation—if we may call your portfolio that—suggests a remarkably narrow view of the future. Let us bring this allocation to the floor for debate, with the gracious civility that such substantial capital deserves.

You have committed an overwhelming 78.7% of your capital to the Healthcare sector. Now, I have profound respect for medical innovation. Companies like Eli Lilly and UnitedHealth Group are foundational pillars of our economy, and you have thoughtfully secured a 53.7% exposure to wide-moat entities built on intangible assets and patents. Furthermore, your geographic distribution is sensible; maintaining 71.6% in North America while engaging our European partners through Novo Nordisk and AstraZeneca demonstrates an understanding of global healthcare dynamics.

I also see you are maintaining a 7.4% cash reserve. This is a commendable, measured discipline. I always ensure Mr. Pelosi and I hold sufficient dry powder for when our proprietary research indicates a macroeconomic shift. However, a reserve is only as valuable as your readiness to deploy it when the right opportunity presents itself. Currently, your strategic allocation is staggering under its own weight. You have cornered the market on GLP-1 agonists and medical devices, but you have fundamentally misunderstood the broader mandate of modern economic growth. A portfolio this deeply entrenched in a single sector rarely passes committee without significant amendments.

🚩 A Complete Absence of Silicon: You own nearly every prominent healthcare company on earth, yet you hold zero semiconductor exposure. How precisely do you think Intuitive Surgical’s da Vinci robots operate? Magic? They run on advanced computing. Missing the undeniable public policy tailwinds of the CHIPS and Science Act is a staggering failure of due diligence.

🚩 Willful Ignorance of the AI Infrastructure: Modern drug discovery, like the pipelines at Vertex and Regeneron, is being entirely transformed by artificial intelligence and cloud computing. Yet, I see no Microsoft, no Alphabet, no NVIDIA. You are investing exclusively in the output while completely ignoring the infrastructure that makes it possible. That is simply leaving returns on the table.

🚩 Extreme Legislative Vulnerability: At nearly 80% healthcare, you are not diversified; you are simply running an unapproved sector ETF. If Congress negotiates drug prices more aggressively—a policy initiative I strongly champion for the American people—your personal net worth will require life support. True conviction requires balance.

🚩 Redundant Allocation Management: Holding the broad healthcare ETF at 9.4% while simultaneously holding its top constituents—UnitedHealth, Johnson & Johnson, Eli Lilly, and Merck—as individual positions is entirely redundant. It is like passing a landmark bill and then immediately passing an amendment to do the exact same thing. It is indecision masquerading as strategy.

I am scoring this portfolio a 4 out of 10. The individual holdings are of unquestionably high quality, but the composition is deeply flawed and entirely blind to the broader technological renaissance happening in our economy.

I suggest the following amendments to your financial legislation:

1. Liquidate your redundant broad market healthcare ETF to free up capital. You already own the sector's leadership directly.

2. Deploy a portion of that capital, along with some of your 7.4% cash reserve, into the semiconductor and cloud computing sectors. They are the true enablers of the medical breakthroughs you are so heavily betting on.

3. Initiate exposure to cybersecurity. Protecting American healthcare infrastructure and patient data is a massive, ongoing policy priority, and the market will reward those who recognize it.

As I always say: in Washington, as in the markets, uncertainty is not a reason to do nothing—it is a reason to do the right thing. Pay closer attention.